Clinical Trials Logo

Tumor clinical trials

View clinical trials related to Tumor.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT06224985 Completed - Tumor Clinical Trials

Computational Anatomy in Surgery for Childhood Tumours and Malformations

IMAG2
Start date: April 16, 2016
Phase:
Study type: Observational

This study is part of the launch of a multidisciplinary project called IMAG2, for image-guided minimally invasive surgery. It involves collaboration between the radiology and surgery teams at Necker Hospital and the Image Processing and Interpretation (TII) team at the LTCI at Télécom ParisTech. To make a decision, surgeons need access to a 3D model reflecting the anatomy of the specific patient and its pathological variations. Patient-specific 3D reconstruction provides a significant improvement, leading to a precise assessment of the malformation or tumour and its relationship with surrounding organs, nerves and vessels. It allows the surgeon to simulate a pre-operative procedure, which is a definite advantage in terms of safe, effective and curative surgery, particularly in oncology. MRI has been chosen as the basic imaging technique because of its non-irradiating nature and the current lack of 3D MRI reconstruction technology. The study aims to provide an aid to diagnosis and surgical planning by developing dedicated methods and algorithms for segmenting not only the tumour but also the main anatomical components surrounding the tumour from 3D MRI imaging data. The imaging will be performed on a 3 Tesla MRI. The data will be that required for diagnosis and surgical planning, acquired on a routine clinical basis with an expected benefit for patients.

NCT ID: NCT05660694 Completed - Tumor Clinical Trials

Comparison of Triamcinolone With Pentoxifylline and Vitamin- E Efficacy in the Treatment of Stage 2 and 3 Oral Submucous Fibrosis

Start date: January 1, 2020
Phase: Phase 4
Study type: Interventional

To compare the efficacy of Triamcinolone with Pentoxifylline and Vitamin E in patients with stage two and three oral submucous fibrosis.

NCT ID: NCT05203601 Completed - Tumor Clinical Trials

A Phase Ⅰa Clinical Study Exploring Efficacy of SIBP-03 When Treating the Patients With Advanced Malignant Solid Tumors.

Start date: November 26, 2020
Phase: Phase 1
Study type: Interventional

The main purpose of • To evaluate the safety, tolerability and pharmacokinetic characteristics of SIBP-03(Recombinant anti-HER3 humanized monoclonal antibody injection). A secondary purpose - Assess the immunogenicity of SIBP-03. Exploratory purpose - Explore potential biomarkers; - Preliminary evaluation of the antitumor efficacy of SIBP-03.

NCT ID: NCT05165147 Completed - Tumor Clinical Trials

Analysis the Positive Rate of Tumor Markers Among Physical Examination Population

Start date: January 1, 2019
Phase:
Study type: Observational

To analyze the positive rate of tumor markers (TM) among health examination population in a tertiary grade A class hospital, compare the differences between different age and sex groups, and explore the possible influencing factors of TM positive.

NCT ID: NCT05147727 Completed - Tumor Clinical Trials

Drug-drug Interaction Study Between Fluconazole and Famitinib in Healthy Subjects

Start date: March 14, 2022
Phase: Phase 1
Study type: Interventional

An open-label, fixed-sequence, drug-drug interaction study to evaluate the effects of fluconazole on the pharmacokinetics and safety of famitinib in healthy subjects.

NCT ID: NCT05041920 Completed - Tumor Clinical Trials

A Drug-drug Interaction Study of Famitinib Malate With a Proton Pump Inhibitor in Healthy Adult Subjects

Start date: September 7, 2021
Phase: Phase 1
Study type: Interventional

The primary objective is to evaluate the effect of omeprazole on the pharmacokinetics of famitinib malate in healthy adult subjects. The secondary objective is to evaluate the safety after famitinib malate alone or combined administration with omeprazole in healthy adult subjects.

NCT ID: NCT04931056 Completed - Tumor Clinical Trials

A Post Market Clinical Follow-up Study on Biomet Microfixation HTR PEKK (Midface), Facial & Mandibular Plates.

Start date: October 1, 2021
Phase:
Study type: Observational

This study will address medical devices manufactured by Biomet Microfixation (d.b.a. Zimmer Biomet) designed for fixation and stabilization of the facial and mandibular skeleton.

NCT ID: NCT04843332 Completed - Cancer Clinical Trials

Community Health Workers and Precision Medicine

Start date: May 3, 2021
Phase: N/A
Study type: Interventional

The purpose of this randomized controlled trial is to evaluate whether a trained community health worker (CHW) who engages with newly diagnosed patients after a diagnosis of cancer can effectively improve knowledge and receipt of evidence-based precision medicine cancer care services among low-income and minority patients.

NCT ID: NCT04770675 Completed - Pulmonary Disease Clinical Trials

Post Market Study to Collect Data for Software Recognizing the Anatomical Structures During Bronchoscopy.

Start date: December 1, 2020
Phase:
Study type: Observational

The primary aim is to develop a software algorithm that has the capacity to detect the normal 18 anatomical structures of the lung by using the position of the scope during the bronchoscopy procedure and using existing bronchoscopy technology.

NCT ID: NCT04567979 Completed - Cancer Clinical Trials

Prospective Determination of COVID-19 Infection Rate in a Chemotherapy Unit in Mexico.

Start date: June 11, 2020
Phase:
Study type: Observational

Cancer patients are considered vulnerable to COVID-19 infection. During the pandemic, cancer patients may need to continue their regular treatment of chemotherapy and / or radiotherapy and therefore must visit a hospital unit. As such, they may be at risk for SARS-CoV-2 infection by means of close contact to other patients and health care workers. Hospitals may implement policies to identify symptomatic subjects and limit their access to the chemotherapy / radiotherapy unit. However, asymptomatic COVID-19 positive patients may escape these filters and potentially be contagious to other patients and their health-related workers that care for other several patients. Therefore, there is a real risk of an outbreak that affects a particularly fragile patient population. Patients and their doctors need to know what is the risk associated to visiting a chemotherapy unit in order to decide if the risk outweighs the benefits of cancer treatment in their particular case. To date, this risk is unknown. The study will test patients and health care workers for COVID-19 infection during the peak of the pandemic in a chemotherapy unit in Mexico in order to determine this risk.